Researchers describe a recent case report of a diagnosis of lgE monoclonal gammopathy which transformed into myeloma, then into lgE-producing plasma cell leukemia.
An abnormal free light chain ratio must be considered as a possible marker of lgE monoclonal gammopathy, researchers concluded following a recent case report of a diagnosis of lgE monoclonal gammopathy which transformed into myeloma, then into lgE-producing plasma cell leukemia.
The case study, published by Biochemia Medica, involved a 71-year-old male who was followed in Brest, France, from 2015 to 2019. Hypogammaglobulinemia was detected during a systematic check-up in November 2015 and a kappa light chain monoclonal gammopathy was first diagnosed due to an increase of the free kappa/lambda chains ratio. The authors noted that no monoclonal immunoglobulin was detected by either serum protein electrophoresis or immunofixation.
“The IgE-producing variant is the rarest sub-type of multiple myeloma, and plasma cell leukemia is considered to be the rarest and the most aggressive of human monoclonal gammopathies,” the researchers noted. “Plasma cell leukaemia (PCL) is considered to be the rarest of human monoclonal gammopathy, accounting for 0.04 cases per 100,000 persons per year in Europe and also the most aggressive. It can either develop de novo (primary PCL) or evolve as a late-stage complication of MM (secondary PCL, sPCL) occurring in less than 1% of MM cases.”
The patient was diagnosed with plasma cell leukemia following a blood smear in June 2018. Additionally, a monoclonal peak was detected and identified as IgE-kappa. Three years later, an archival sample was taken, revealing the presence of a monoclonal IgE that was missed at diagnosis, and chemotherapy with bortezomib and dexamethasone was introduced to the patient.
Following the diagnosis of leukemia the patient survived 10 months. The researchers suggest that abnormal free light chain could be a possible marker of IgE monoclonal gammopathy, even when there is an absence of a solitary light chain by immunofixation.
Also, the case study suggested that the use of an undilated serum may increase the sensitivity of the immunofixation for the detection of IgE monoclonal gammopathies compared to the 1:3 dilution recommended by the manufacturer.
“The medical laboratory plays an important role in the proper diagnosis and quality of management of MM patients. This case revealed that an abnormal FLC ratio should be considered as a warning signal suggesting the possibility of IgD or IgE myeloma even in the absence of a solitary light chain in IFE,” the study concluded. “Further investigation is warranted to evaluate the diagnostic strategy of systematically testing IgD and IgE with IFE in the presence of an abnormal FLC ratio.”
Reference
Galakhoff N, Leven C, Eveillard JR, et al. A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia. Biochem Med (Zagreb). 2020;30(1):010801. doi:10.11613/BM.2020.010801.
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma
June 18th 2024The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden
December 22nd 2023Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More